TREATMENT OF INFLAMMATORY BOWEL DISEASES WITH HUMAN BETA DEFENSIN PROTEINS 1-4

摘要

Discloses the use of human beta defensin peptides (1-4), encoded by SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4, in the manufacture of a medicament adapted for parenteral administration in the treatment of an inflammatory bowel disease. The medicament may be administered subcutaneously or intravenously in a daily dosage from 0.001 mg/kg body weight to about 10 mg/kg body weight, where the use of the medicament results in a reduction of TNF-alpha activity is reduced in the treated tissues.